ArticleInternational neurourology journal2025
Efficacy of Holmium Laser Enucleation of the Prostate in Patients With Detrusor Underactivity or Acontractile Bladder.
Article in International neurourology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluates the efficacy of holmium laser enucleation of the prostate (HoLEP) as a deobstructive surgical intervention for patients with detrusor underactivity (DU) or an acontractile bladder (AcB).
methodsBetween April 2021 and May 2024, patients undergoing HoLEP for benign prostatic obstruction (BPO) were selected based on urodynamic study results indicating DU or AcB. The primary outcome was the change in voiding efficiency (VE) following HoLEP. Secondary outcomes included differences in VE between subgroups, such as the DU and AcB groups. The VE trend over time was visualized using Python's Seaborn library with the locally weighted scatterplot smoothing method, and plots were generated using Matplotlib.
resultsFourteen patients with DU and 12 patients with AcB underwent HoLEP during the study period. In the DU group, the median age was 76.5 years, with a prostate size of 48.6 mL and 39% of tissue resected. In contrast, the AcB group had a median age of 74.5 years, a prostate size of 68 mL, and 44.5% of tissue resected. The median duration from symptom onset to surgery was 4.3 years in the DU group and 0.8 years in the AcB group. The median preoperative VE was 0% (n=26), which significantly increased to 81.3% postoperatively (P=0.0). VE increased sharply up to one month postoperatively, then plateaued. Additionally, other voiding functions showed statistically significant improvements in maximum urine flow (0 mL/sec vs. 14.4 mL/sec, P=0.0) and postvoid residual (325 mL vs. 45 mL, P=0.0). No significant difference in VE was found between the DU and AcB groups.
conclusionHoLEP effectively improves VE and symptoms as a deobstructive surgical intervention for patients with BPO and DU or AcB. There was no significant difference in outcomes between patients with DU and AcB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.